Australian scientists thought to be on the verge of curing paralysis
Australian scientists at Griffith University will launch clinical trials in early 2025 using olfactory nerve cells to treat spinal cord injuries, aiming to repair nerves and restore function for patients.
Read original article
Australian scientists at Griffith University are preparing to launch world-first clinical trials aimed at curing paralysis through innovative spinal cord injury treatments. Set to begin in early 2025, these trials will utilize olfactory nerve cells harvested from patients' noses, which have unique therapeutic properties. The process involves purifying these cells and creating specialized nerve bridges that will be transplanted into the spinal cord injury site. This groundbreaking approach is based on the research of the late Professor Alan Mackay-Sim and aims to repair and regenerate damaged nerves, potentially allowing patients to regain function and sensation. The trials will also include intensive rehabilitation for participants. With over 20,000 Australians currently living with spinal cord injuries, the research holds promise for significant advancements in treatment. Professor James St John emphasized the importance of designing the trial in collaboration with the spinal injury community to ensure its success. The trial is seeking volunteers with chronic spinal cord injuries, particularly those who have had their injuries for at least 12 months.
- Griffith University is set to begin pioneering spinal cord injury trials in early 2025.
- The trials will use olfactory nerve cells from patients' noses to create nerve bridges for transplantation.
- The research aims to repair damaged nerves and restore function to individuals with spinal cord injuries.
- Over 20,000 Australians are affected by spinal cord injuries, highlighting the potential impact of this treatment.
- The trial is designed with input from the spinal injury community to maximize its chances of success.
Related
Mapping the biology of spinal cord injury in unprecedented detail
EPFL researchers develop 'Tabulae Paralytica' atlas using AI and molecular mapping to study spinal cord injuries in mice. Identifies key genes, challenges astrocyte roles, and highlights Vsx2 neurons for recovery. Published in Nature, the study offers insights for potential gene therapy.
Bugs, drugs and electric venom: is this the most deadly library in the world?
Scientists in Brisbane, led by Andrew Walker, study venom from various animals, including caterpillars, for potential medical and agricultural benefits. Their research aims to develop targeted therapeutics using venom-derived molecules.
Brain-to-Speech Tech Good Enough for Everyday Use Debuts in a Man with ALS
Casey Harrell, a man with ALS, regained communication through a new brain-computer interface with under 3% error. This advancement in speech neuroprostheses faces challenges but offers transformative potential for many.
Covid-19 Intranasal Vaccine
Griffith University developed an intranasal COVID-19 vaccine, CDO-7N-1, offering long-term protection, stability at 4°C, and effectiveness against major variants. It is licensed for clinical trials by Indian Immunologicals Ltd.
Magnetically regulated gene therapy offers precise brain-circuit control
Researchers at Weill Cornell Medicine and others developed a non-invasive gene therapy using magnetic fields to control brain circuits, showing promise for treating Parkinson's disease and other neurological disorders.
1 commentsRelated
Mapping the biology of spinal cord injury in unprecedented detail
EPFL researchers develop 'Tabulae Paralytica' atlas using AI and molecular mapping to study spinal cord injuries in mice. Identifies key genes, challenges astrocyte roles, and highlights Vsx2 neurons for recovery. Published in Nature, the study offers insights for potential gene therapy.
Bugs, drugs and electric venom: is this the most deadly library in the world?
Scientists in Brisbane, led by Andrew Walker, study venom from various animals, including caterpillars, for potential medical and agricultural benefits. Their research aims to develop targeted therapeutics using venom-derived molecules.
Brain-to-Speech Tech Good Enough for Everyday Use Debuts in a Man with ALS
Casey Harrell, a man with ALS, regained communication through a new brain-computer interface with under 3% error. This advancement in speech neuroprostheses faces challenges but offers transformative potential for many.
Covid-19 Intranasal Vaccine
Griffith University developed an intranasal COVID-19 vaccine, CDO-7N-1, offering long-term protection, stability at 4°C, and effectiveness against major variants. It is licensed for clinical trials by Indian Immunologicals Ltd.
Magnetically regulated gene therapy offers precise brain-circuit control
Researchers at Weill Cornell Medicine and others developed a non-invasive gene therapy using magnetic fields to control brain circuits, showing promise for treating Parkinson's disease and other neurological disorders.